Disease · MONDO_0011385
intervertebral disk degenerative disorder
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. intervertebral disk degenerative disorder. Diseases, record MONDO_0011385. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011385
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Degeneration of intervertebral discs, Degeneration of intervertebral disks, Degenerative disc disease, Degenerative intervertebral disc, Degenerative intervertebral disk, IDD, degenerative disc disorder, degenerative disk disease, degenerative disorder of intervertebral disc, degenerative disorder of intervertebral disk, intervertebral Disc Degeneration, intervertebral Disc degenerative disease, intervertebral Disc degenerative disorder, intervertebral disc disease, intervertebral disk degeneration, intervertebral disk disease, lumbar disc degeneration, vertebral Disc degenerative disease, vertebral Disc degenerative disorder, vertebral disk disease
- Open Targets
- Highest stage of its drugs
- Phase 3, for 2 of its 8 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| REBONUPUTEMCEL | CHEMBL4802266 | Cell | Phase 3 | ClinicalTrials.gov | 5 | 3 | 3 | Drugs and targets |
| REXLEMESTROCEL-L | CHEMBL3545318 | Cell | Phase 3 | TTD | 4 | 3 | 3 | Drugs and targets |
| RADOTERMIN | CHEMBL2108637 | Protein | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PAMIDRONIC ACID | CHEMBL834 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRANEXAMIC ACID | CHEMBL877 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LORECIVIVINT | CHEMBL4297639 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TIGECYCLINE | CHEMBL376140 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
Targets4
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CLK2 | Dual specificity protein kinase CLK2 | 1 | Dual specificity protein kinase CLK2 inhibitor | Phase 1 | https://conductscience.org/library/genes/1196 | Drugs and targets |
| DYRK1A | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | 1 | Dual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor | Phase 1 | https://conductscience.org/library/genes/1859 | Drugs and targets |
| FDPS | Farnesyl pyrophosphate synthase | 1 | Farnesyl diphosphate synthase inhibitor | Phase 2 | https://conductscience.org/library/genes/2224 | Drugs and targets |
| PLG | Plasminogen | 1 | Plasminogen inhibitor | Phase 2 | https://conductscience.org/library/genes/5340 | Drugs and targets |
Trials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04272606 | TXA in Spinal Fusion | Phase 2 | 123 | 2024-05-14 | Degenerative Disc Disease | SODIUM CHLORIDE, TRANEXAMIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT01158924 | A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration | Phase 1/2 | 40 | 2016-01-27 | Early Lumbar Disc Degeneration | RADOTERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT00813813 | Intradiscal rhGDF-5 Phase I/II Clinical Trial | Phase 1/2 | 32 | 2016-01-27 | Degenerative Disc Disease | RADOTERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT01182337 | A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration | Phase 1/2 | 31 | 2016-01-27 | Early Lumbar Disc Degeneration | RADOTERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT01124006 | A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration | Phase 2 | 24 | 2016-02-24 | Degenerative Disc Disease | RADOTERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT07254806 | A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease | Phase 3 | 162 | Degenerative Disc Disease | REBONUPUTEMCEL | Its record names the disease | ClinicalTrials.gov | |
| NCT03347708 | Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration | Phase 1 | 60 | Degenerative Disc Disease | REBONUPUTEMCEL | Its record names the disease | ClinicalTrials.gov | |
| NCT01799616 | Efficiency and Safety Study of Pamidronate in Inflammatory Back Pain Due to Degenerative Disk Disease | Phase 2 | 48 | Intervertebral Disc Degeneration, Modic I Discopathy, Back Pain, Low Back Pain, Magnetic Resonance Imaging (MRI) | PAMIDRONIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT03955315 | Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration | Phase 1 | 38 | Degenerative Disc Disease | REBONUPUTEMCEL | Its record names the disease | ClinicalTrials.gov | |
| NCT01097486 | Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy | Phase 2 | 24 | Cervical Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis | REXLEMESTROCEL-L | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 13
See all 13 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Treatment vs Placebo: deaths from any cause | 0 of 43 | 0 of 40 | 83 | NCT04272606 | Trial comparisons |
| Treatment vs Placebo: serious adverse events | 0 of 43 | 2 of 40 | 83 | NCT04272606 | Trial comparisons |
| Intradiscal rhGDF-5 (1.0mg) vs Intradiscal rhGDF-5 (2.0mg): Treatment Emergent Adverse Events- Relationship to Study Drug | 2 of 14 | 1 of 26 | 40 | NCT01158924 | Trial comparisons |
| Intradiscal rhGDF-5 (1.0mg) vs Intradiscal rhGDF-5 (2.0mg): serious adverse events | 1 of 14 | 4 of 26 | 40 | NCT01158924 | Trial comparisons |
| Intradiscal rhGDF-5 (1.0mg) vs Intradiscal rhGDF-5 (2.0mg): Neurological Assessment for Motor Function and Reflexes/Sensory | 0 of 13 | 2 of 25 | 38 | NCT01158924 | Trial comparisons |
| Intradiscal rhGDF-5 (0.25mg) vs Intradiscal rhGDF-5 (1.0mg): Neurological Assessment for Motor Function and Reflexes/Sensory | 0 of 7 | 0 of 25 | 32 | NCT00813813 | Trial comparisons |
| Intradiscal rhGDF-5 (0.25mg) vs Intradiscal rhGDF-5 (1.0mg): Treatment Emergent Adverse Events- Relationship to Study Drug | 2 of 7 | 1 of 25 | 32 | NCT00813813 | Trial comparisons |
| Intradiscal rhGDF-5 (0.25mg) vs Intradiscal rhGDF-5 (1.0mg): serious adverse events | 2 of 7 | 2 of 25 | 32 | NCT00813813 | Trial comparisons |
| Intradiscal rhGDF-5 vs Vehicle Control: Treatment Emergent Adverse Events- Relationship to Study Drug | 0 of 22 | 1 of 9 | 31 | NCT01182337 | Trial comparisons |
| Intradiscal rhGDF-5 1.0mg vs Vehicle Control: Treatment Emergent Adverse Events- Relationship to Study Drug | 0 of 22 | 0 of 9 | 31 | NCT01182337 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011385
GET https://conductscience.org/api/diseases/v1/MONDO_0011385/drugs